Q1 2023 Non-GAAP Operating Income

Q1 2023 Summary $ millions, except EPS Q1 2023 Q1 2022 Q1 2023 Q1 2022 GAAP Non-GAAP Revenues* 3,661 3,661 3,661 3,661 Operating income (loss) 2 (713) 785 1,013 Net income (loss) attributable to Teva (205) (955) 457 609 (0.18) (0.86) 0.40 0.55 Earnings (loss) per share ($)** 1,115 million shares 1,107 million shares 1,128 million shares 1,112 million shares | 18| ** Revenues are presented on a GAAP basis Earnings per share based on a fully diluted basis teva

View entire presentation